arrow
N

Nuria Ribelles

hospital virgen de la victoria
H指数:32
被引数:4,801

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical features and management for CDK4/6 inhibitor-DILI

CDK4/6抑制剂相关药物性肝损伤的临床特征与管理

2026-04-290
OAAI
Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy

新辅助化疗后三阴性乳腺癌辅助卡培他滨的真实世界数据分析

2025-11-180
OAAI
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records
2024-10-200
OAAI
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
2024-04-044
OA
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
LANCET
IF88.5
2024-04-0116
PRE
ESMO Guidance for Reporting Oncology real-World evidence (GROW)

报告肿瘤学真实世界证据的ESMO指南 (GROW)

2023-12-0137
OAAI
Increasing blood volumes to detect minimal residual disease in neoadjuvant-treated early breast cancer patients
2023-04-040
PRE
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients
2021-02-019
OAAI
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome
2020-09-185
PREAI
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
2019-11-0511
OAAI
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

帕妥珠单抗联合曲妥珠单抗和紫杉烷一线治疗HER2-positive局部复发或转移性乳腺癌的初步安全性和有效性 (PERUSE)

2019-05-0189
OAAI